Interview: Fabrizio Greco – General Manager, AbbVie Italy
Fabrizio Greco, General Manager at AbbVie Italy, discusses the successful launch of the company’s new Hepatitis C treatment, how AbbVie is seeking to position itself as a partner to the…
Address: Viale Shakespeare, 47 – 00144 Rome,Italy
Tel: +39.06.592.64.43
Sigma-tau is a leading Italian pharmaceutical group, established in 1957 that counts today 2432 employees worldwide amongst whom about 400 researchers. It reached a turnover of 605 million euros in 2008.
The headquarters of the group are in Pomezia, and Sermoneta – in the province of Latina- has active installations Biosint for the production of pharmaceutical raw materials, of L-carnitine and its derivatives.
In 2001 was established BiofuturaPharma, based in Milan, that aims to develop pharmaceuticals for the treatment of diseases of the central nervous system and respiratory system. Recently the business has extended to the development and commercialization of products derived from the biological system of carnitine.
Sigma-Tau works through the National Organization for Rare Disorders (NORD) to provide patient assistance programs to help ensure that patients who are underinsured or otherwise financially limited receive their products at little or no cost.
Always investing in research, 16% of turnover in 2008, Sigma-tau aims to continue its development by:
* Increasing commitment to research in biopharma
* Continuous technological upgrading of production systems
* High-quality products
Fabrizio Greco, General Manager at AbbVie Italy, discusses the successful launch of the company’s new Hepatitis C treatment, how AbbVie is seeking to position itself as a partner to the…
Enrique Hausermann, CEO of EG, the Stada Group’s Italian affiliate for its generics business, discusses the progress the company has made since 2009, the promising areas for growth he sees…
CFCII’s Director provides us with an overview of the services offered to French and Italian companies by the Chamber, as well as her perceptions about investments between the two countries,…
Alberto Gugliemo, President of the Carlo Besta Institute in Milan, shares the changing perception of neurological diseases and neurological science in Italy, the nature of the institute’s collaboration with the…
Francesco Carugi, Managing Director at Grifols Italy, discusses the company’s presence in the plasma, plasma products and plasma diagnostics segments, the impact of the liberalization of the Italian plasma market on…
Dr. Giorgio Pisani, President and CEO of IBSA Italy, talks about his founding of the company in 2001 and its rapid growth in the market through a combination of organic…
Prof. Walter Ricciardi has just been appointed as the new president for the Italian National Institute of Health (ISS). He explains his priorities since taking office, the crucial role the…
Paolo Casati, general manager for Santen’s new affiliate in Italy, discusses the company’s first full year in the country, its aims for contributing to the global group’s 2020 Vision by…
Paolo Cionini, General Manager of LEO Pharma Italy, discusses the initial challenges of setting up the Italian affiliate during the height of the global financial crisis in 2011, the company’s…
Sofia Astrid Pennacchi, Secretary General of the British Chamber of Commerce for Italy, discusses the various services the Chamber offers its members, the positive effects the Expo has had on…
Giulio Volpe, Managing Director of Lundbeck’s Italian API’s production plant, discusses what is leading multinational companies to relocate their production to Italy, the value the Italian plant can offer the…
Enrico Allievi, President of the Italian OTC (Over The Counter) association, Assosalute, talks about the state of the OTC market in Italy, as well as the association’s role in creating…
See our Cookie Privacy Policy Here
